# EDGAR Filing Document

**Accession Number:** 0001683913
**File Stem:** 0001562180-25-005346
**Filing Date:** 2025-7
**Character Count:** 10416
**Document Hash:** 36b97b29f80a53cb7c265cad7936d270
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562180-25-005346.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001562180-25-005346

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250704

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Huang Jane
- **CENTRAL INDEX KEY:** 0001683913

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39527
- **FILM NUMBER:** 251111115

**MAIL ADDRESS:**
- **STREET 1:** C/O MOURANT OZANNES CORPORATE SERVICES
- **STREET 2:** 94 SOLARIS AVENUE
- **CITY:** CAMANA BAY, GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1-1108
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prelude Therapeutics Inc
- **CENTRAL INDEX KEY:** 0001678660
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811384762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805
- **BUSINESS PHONE:** (302) 467-1280

**MAIL ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prelude Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20160630

## Ex-24

```

POWER OF ATTORNEY

      KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned
hereby constitutes and appoints Prelude Therapeutics
Incorporated's Chief Executive Officer, Chief Financial Officer,
and the Chief Legal Officer and each of them, as their true and
lawful attorney-in- fact to:
            (1)	execute for and on behalf of the undersigned, in
the undersigned's capacity as a representative of Prelude
Therapeutics Incorporated (the "Company"), any and all Form ID,
or Form 3, 4 or 5 reports and any amendments thereto required to
be filed by the undersigned in accordance with Section 16(a) of
the Securities Exchange Act of 1934 (the "Exchange Act") and the
rules thereunder with respect to transactions in the Company's
securities;
            (2)	do and perform any and all acts for and on behalf
of the undersigned which may be necessary or desirable to
complete and execute any such Form ID, or Form 3, 4 or 5 report
and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or
similar authority; and
            (3)	take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of,
or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in his or her discretion.
      The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform each and every act
and thing whatsoever requisite, necessary, and proper to be done
in the exercise of any of the rights and powers herein granted,
as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution
or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or his or her substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of
Attorney and the rights and powers herein granted. The
undersigned acknowledges that no such attorney-in-fact, in
serving in such capacity at the request of the undersigned, is
hereby assuming, nor is the Company hereby assuming, any of the
undersigned's responsibilities to comply with Section 16 of the
Exchange Act.
      The undersigned agrees that each such attorney-in-fact may
rely entirely on information furnished orally or in writing by
the undersigned to each such attorney-in-fact. The undersigned
also agrees to indemnify and hold harmless the Company and each
such attorney-in-fact against any losses, claims, damages or
liabilities (or actions in these respects) that arise out of or
are based on any untrue statement or omission of necessary facts
in the information provided by the undersigned to such attorney-
in-fact for purposes of executing, acknowledging, delivering and
filing Forms 3, 4 or 5 (including amendments thereto) and agrees
to reimburse the Company and each such attorney-in-fact for any
legal or other expenses reasonably incurred in connection with
investigating or defending against any such loss, claim, damage,
liability or action.

      This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Form 3, 4 or 5
reports with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
      IN WITNESS WHEREOF, the undersigned has executed this Power of
Attorney as of the date set forth below.

Signature: /s/ Jane Huang

Printed Name: Jane Huang

Date: July 7, 2025

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Huang Jane<br><sub>(Last) (First) (Middle)</sub><br>C/O PRELUDE THERAPEUTICS INCORPORATED<br>175 INNOVATION BOULEVARD<br><sub>(Street)</sub><br>WILMINGTON, DE 19805<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President, CMO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Prelude Therapeutics Inc [ PRLD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-07-04 |  | M |  | 9375.00 | A | <sup>(1)</sup> | 84252.00 | D |  |
| Common Stock | 2025-07-04 |  | F |  | 3355.00<sup>(2)</sup> | D | $0.7939 | 80897.00 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2025-07-04 |  | M |  |  | 9375.00 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 9375.00 | $0.00 | 28125.00 | D |  |

---

### Footnotes:

(1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.

(2) Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.

(3) The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

**Signature:** /s/ Bryant D. Lim, Attorney-in-Fact  
**Date:** 2025-07-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**